Pl find enclosed herewith the outcome of the BM dated 28th May, 2026. The meeting of the Board of Directors of the Company commenced at 11.20 am and concluded at 13.15 pm.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alkem Laboratories Board approved audited standalone and consolidated financial results for Q4 and FY ended March 2026. Consolidated revenue grew 13.5% year-on-year to Rs. 147,123 million, with profit after tax at Rs. 23,512 million (up 6.1%). Exceptional items of Rs. 1,748.3 million impacted profits, comprising real estate impairment of Rs. 747 million and labour code provisions of Rs. 1,130.6 million. The Board recommended a final dividend of Rs. 10 per share (adding to Rs. 43 interim already paid), taking total dividend to Rs. 53 per share. The 52nd AGM is scheduled for 27th August 2026 with record date 7th August 2026 for dividend. Mrs. Madhurima Singh was re-appointed as Executive Director for 5 years from December 2026. Auditors Deloitte issued unmodified opinions on both standalone and consolidated results.
Strong full-year revenue growth of 13.5% with clean audit opinions is positive for shareholders. Total dividend of Rs. 53 per share provides good returns. One-time exceptional charges reduced Q4 profits but underlying business remains healthy.